CHM-1101 is under clinical development by Chimeric Therapeutics and currently in Phase I for Malignant Glioma. According to GlobalData, Phase I drugs for Malignant Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CHM-1101 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CHM-1101 overview
CHM-1101 is under development for the treatment of recurrent or progressive glioblastoma multiforme, astrocytoma, malignant glioma and solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer. It is administered through intracranial intratumoral and intracranial intraventricular routes. The therapeutic candidate comprises of autologous T cells genetically modified to express chimeric antigen receptor (CAR-T) that is fused with scorpion-derived peptide chlorotoxin (CLTX) targeting CD19.
Chimeric Therapeutics overview
Chimeric Therapeutics, a subsidiary of Cell and Gene Therapy Catapult, is a clinical-stage cell therapy company that discovers and develops therapies for the treatment of cancer. The company focuses on the development of cell-based allogenic and autologous therapies. It is investigating CHM1301 and CHM 2301 programs against solid tumors; CHM 0301, to treat blood cancer and CHM 0201, for hematological malignancies disorder and solid tumors. Chimeric Therapeutics is also developing chimeric antigen receptor (CAR) T cell-based therapies such as CHM 1101 program for the treatment of glioblastoma, melanoma and colorectal cancer and CHM 2101 against Neuroendocrine cancer. Chimeric Therapeutics is headquartered in Carlton, Victoria, Australia.
For a complete picture of CHM-1101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
